Athersys, Inc. (NASDAQ:ATHX) Receives Consensus Recommendation of “Strong Buy” from Brokerages
Athersys, Inc. (NASDAQ:ATHX) has been given a consensus broker rating score of 1.00 (Strong Buy) from the three analysts that provide coverage for the company, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy recommendation.
Brokerages have set a 1 year consensus target price of $9.00 for the company and are predicting that the company will post ($0.06) EPS for the current quarter, according to Zacks. Zacks has also assigned Athersys an industry rank of 159 out of 265 based on the ratings given to its competitors.
Several research analysts have issued reports on the stock. William Blair restated an “outperform” rating on shares of Athersys in a research report on Tuesday, March 28th. Maxim Group set a $9.00 price target on shares of Athersys and gave the company a “buy” rating in a report on Monday, March 20th. Finally, Zacks Investment Research upgraded shares of Athersys from a “hold” rating to a “buy” rating and set a $1.25 price target on the stock in a report on Tuesday, March 14th.
Athersys (NASDAQ:ATHX) traded down 3.143% during mid-day trading on Monday, reaching $1.695. The company’s stock had a trading volume of 549,287 shares. The firm’s market capitalization is $188.68 million. The stock’s 50-day moving average is $1.48 and its 200-day moving average is $1.40. Athersys has a 12 month low of $1.02 and a 12 month high of $2.35.
Athersys (NASDAQ:ATHX) last released its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.07) by $0.01. Athersys had a negative return on equity of 135.04% and a negative net margin of 765.65%. The company had revenue of $1.50 million for the quarter, compared to analysts’ expectations of $0.45 million. During the same quarter in the previous year, the company posted $0.06 earnings per share. The business’s revenue for the quarter was down 90.3% compared to the same quarter last year. On average, equities analysts anticipate that Athersys will post ($0.26) EPS for the current year.
In other Athersys news, EVP John J. Harrington sold 36,000 shares of the business’s stock in a transaction on Friday, June 16th. The shares were sold at an average price of $1.45, for a total transaction of $52,200.00. Following the completion of the transaction, the executive vice president now owns 712,743 shares of the company’s stock, valued at approximately $1,033,477.35. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 9.40% of the stock is owned by insiders.
A number of hedge funds have recently bought and sold shares of ATHX. Goldman Sachs Group Inc. boosted its stake in shares of Athersys by 327.2% in the first quarter. Goldman Sachs Group Inc. now owns 240,056 shares of the biopharmaceutical company’s stock valued at $410,000 after buying an additional 183,867 shares in the last quarter. FNY Partners Fund LP bought a new position in shares of Athersys during the first quarter worth about $206,000. Bank of America Corp DE raised its position in shares of Athersys by 17.2% in the first quarter. Bank of America Corp DE now owns 61,580 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 9,019 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Athersys by 35.2% in the first quarter. Geode Capital Management LLC now owns 756,004 shares of the biopharmaceutical company’s stock worth $1,292,000 after buying an additional 196,981 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Athersys by 19.5% in the first quarter. Vanguard Group Inc. now owns 3,899,200 shares of the biopharmaceutical company’s stock worth $6,668,000 after buying an additional 637,322 shares during the last quarter. 17.73% of the stock is currently owned by institutional investors and hedge funds.
Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Athersys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys Inc. and related companies with MarketBeat.com's FREE daily email newsletter.